Retina

Geographic Atrophy: A New Approach to a Historically Untreatable Disease

Leading retina specialists discuss how the treatment landscape for geographic atrophy is changing, and what it means for patient care.

Overview

LinkedIn Facebook X

Geographic atrophy (GA), an advanced form of dry age-related macular degeneration, has long been one of the most challenging conditions in retina care — a progressive, irreversible disease with no way to slow its course. In this roundtable, three retina specialists discuss how that reality is beginning to change.

Moderated by Dr. Priya Vakharia, the panel explores the science behind GA, how it presents and progresses, and the practical considerations clinicians face when identifying candidates, setting expectations, and integrating new approaches into everyday practice.

The conversation reflects the panelists' own clinical perspectives and experience, offering a candid look at where the field stands today and where it may be headed.

The Panel

Moderator

Dr. Priya Vakharia, MD

Financial disclosures

4DMT, AbbVie, Adverum/Eli Lilly, Alcon, Alexion, Aliph, Allgenesis, ANI Pharmaceuticals, Annexon, Apellis, Astellas, Aviceda, Bausch + Lomb, Bayer, Boehringer Ingelheim, Eyebiotech Limited, EyePoint, Genentech/Roche, Glaukos, Heidelberg Engineering, Ionis, Janssen, Kirwin, Kodiak, Kyoto, Kyowa Kirin, McKesson, Notal Vision, Novartis, Ocular Therapeutix, Oculis, OcuTerra, Ollin Biosciences, Opthea, ONL Therapeutics, Pfizer, Priovant Therapeutics, Recens Medical, Regeneron, Regenxbio, Sanofi, Skyline Therapeutics, Stealth Biotherapeutics and Unity

Dr. David Chin Yee, MD

Financial disclosures

Advisor/consultant (Alcon, Apellis, Astellas, Eyepoint, Genentech, Regeneron); Speakers Bureau (ANI Pharmaceuticals, Apellis, Astellas, Genentech, Regeneron)

Dr. Harit Bhatt, MD